Predicting response to anti-TNF treatment in rheumatoid arthritis patients

Autoimmunity Reviews

Volumn 8, Issue 5, 2009, Pages 431-437

  Atzeni, Fabiola ^a   Antivalle, Marco ^a   Pallavicini, Francesca Bobbio ^b   Caporali, Roberto ^b   Bazzani, Chiara ^c   Gorla, Roberto ^c   Favalli, Ennio Giulio ^d   Marchesoni, Antonio ^d   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Rheumatology and Clinical Immunology Unit   (Italy)

^d UOC Day Hospital of Rheumatology   (Italy)

Author keywords

Anti TNF; DAS 28 response; EULAR response; Factor predictors; LORHEN registry

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; REGISTER; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61549140715     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.01.005     Document Type: Review

References (36)

1. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 (2000) 1594-1602
2. St Clair E.W. Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis 61 Suppl 2 (2002) ii67-ii69
3. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleischmann R.M., Bulpitt K.J., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 (1999) 478-486
4. Hamilton K., and Clair E.W. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. Expert Opin Pharmacother 1 (2000) 1041-1052
5. Klareskog L., van der Heijde D.M.F.M., de Jager J.P., Gough A., Kalden J., and Malaise M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
6. Burmester G.R., Monteagudo Saez I., Malaise M., Canas da Silva J., Webber D.G., and Kupper H. Efficacy and safety of adalimumab (HUMIRA) in European clinical practice: the ReAct trial. Ann Rheum Dis (2004) s63
7. Weimblatt E.M., Keystone E.C., Furst D.E., Kavanaugh A.F., Chartash E.K., and Segurado O.G. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65 (2005) 753-759
8. Gartlehner G., Hansen R.A., Jonas B.L., Thieda P., and Lohr K.N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33 (2006) 2398-2408
9. Weaver A.L., Lautzenheiser R.L., Schiff M.H., Gibofsky A., Perruquet J.L., Luetkemeyer J., et al. The RADIUS Investigators: real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin. 22 (2006) 185-198
10. Duclos M., Gossec L., Ruyssen-Witrand A., Salliot C., Luc M., Guignard S., et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 33 (2006) 2433-2439
11. Wolfe F., and Pincus T. Poor outcome and non-response to DMARD therapy. A study of 6870 rheumatoid arthritis patients. Arthritis Rheum 43 Supp 9 (2002) 695
12. Anderson J.J., Wells G., Verhoeven A.C., and Felson D.T. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43 (2000) 22-29
13. Hyrich K.L., Watson K.D., Silman A.J., and Symmons D.P. British Society for Rheumatology Biologics Register Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45 (2006) 1558-1565
14. Sarzi-Puttini P., Antivalle M., Marchesoni A., Favalli E.G., Gorla R., Filippini M., et al. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 60 (2008) 290-295
15. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
16. Valesini G., Montecucco C., and Cutolo M. Anti-TNF treatment for rheumatoid arthritis. Clin Exp Rheum 4 (2006) 414-423
17. Van Riel P.L.C.M., van Gestel A.M., and Scott D.L. on behalf of the EULAR standing committee for international clinical studies including therapeutic trials. The EULAR handbook of clinical assessment in rheumatoid arthritis (2000), Van Zuiden Communications, Alpen an den Rijn, The Netherlands
18. Ranza R., Marchesoni A., Calori G., Bianchi G., Braga M., Canazza S., et al. The Italian version of the functional disability index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies in rheumatoid arthritis. Clin Exp Rheumatol 11 (1993) 123-128
19. Fransen J., Creemers M.C., and van Riel P.L. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology 43 (2004) 1252-1255
20. Makinen H., Kautiainen H., Hannonen P., and Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Ann Rheum Dis 64 (2005) 1410-1413
21. Favalli E.G., Desiati F., Atzeni F., Sarzi-Puttini P., Caporali R., Bobbio-Pallavicini F., et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev (2008) [Electronic publication ahead of print]
22. Bazzani C., Filippini M., Caporali R., Pallavicini F.B., Favalli E.G., Marchesoni A., et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev (2008) [Electronic publication ahead of print]
23. Kievit W., Fransen J., Oerlemans A.J., Kuper H.H., van der Laar M.A., de Rooij D.J., et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 66 (2007) 1473-1478
24. Mancarella L., Bobbio-Pallavicini F., Ceccarelli F., Falappone P.C., Ferrante A., Malesci D., et al., GISEA group. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 34 (2007) 1670-1673
25. Listing J., Strangfeld A., Rau R., Kekow J., Gromnica-Ihle E., Klopsch T., et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 8 (2006) R66
26. Greenberg J.D., Kishimoto M., Cohen S.B., Olenginski T.P., Harrington T., Kafka S.P., et al. Low baseline joint count attenuates response to anti-TNF agents: what are the goals of biologic therapy?. ACR Meeting Abstract (2005)
27. Fries J.F., Williams C.A., Singh G., and Ramey D.R. Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy. J Rheumatol 24 (1997) 838-844
28. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
29. van der Heijde D., Klareskog L., Boers M., Landewé R., Codreanu C., Bolosiu H.D., et al. TEMPO Investigators: comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 64 (2005) 1582-1587
30. Lee Y.H., Woo J.H., Rho Y.H., Choi S.J., Ji J.D., and Song G.G. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int (Oct 18 2007) [Electronic publication ahead of print]
31. Aletaha D., and Smolen J.S. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology 41 (2002) 1367-1374
32. Buch M.H., Bingham S.J., Bryer D., and Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford). 46 (2007) 1153-1156
33. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229.
34. Voigt L.F., Koepsell T.D., Nelson J.L., Dugowson C.E., and Daling J.R. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 5 (1994) 525-532
35. Hamilton J.D., Thomson E.A., Porter D., Hunter J.A., Madhok R., and Capell H.A. Lifestyle influences on outcome in rheumatoid arthritis. Scott Med J 45 (2000) 137-139
36. Sanmartí R., Gómez-Centeno A., Ercilla G., Larrosa M., Viñas O., Vazquez I., et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 26 (2007) 1111-1118